This stock comparison examines two companies that rarely appear side by side: HSIC, the world's largest provider of healthcare solutions to office-based dental and medical practitioners, and NI, a regulated utility serving roughly four million natural gas and electric customers across six states. They occupy different sectors — healthcare distribution versus utilities — yet both are mid-to-large-cap names facing meaningful catalysts. Traders evaluating relative momentum and investors weighing growth against stability may find this comparison useful. Understanding how each company is positioned across business model, momentum, and risk can clarify which profile better fits current market conditions. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their respective industries.
Henry Schein, Inc. (HSIC) distributes dental and medical products, equipment, technology, and value-added services to practitioners worldwide. Recent market activity reflects renewed optimism around the company's execution. In recent quarters, the firm reported sales growth of roughly 6.7% and raised its full-year sales growth guidance to a range of 4.5% to 5.5%, supported by stable dental demand and market-share gains. Management has outlined a program targeting at least $200 million in operating income improvement, alongside a leaner cost structure. A leadership transition, including a new chief financial officer, and new technology distribution partnerships have added to the narrative. Shares have advanced roughly 15% year to date, with a one-year total return near 36%, and most analysts maintain a "Buy" rating with an average price target above the prevailing price.
NiSource Inc. (NI) operates regulated natural gas and electric utilities, including NIPSCO in Indiana and Columbia Gas across several states. Recent performance has been steady but comparatively muted: shares have added only about 4% year to date, underperforming the broader market. The company's third-quarter report showed adjusted earnings per share of $0.27, beating consensus, though revenue fell slightly short of estimates. NI has extended its capital plan through 2033 to roughly $40 billion and raised its long-term adjusted earnings growth outlook, anchored by a fast-growing GenCo (generation company) segment serving data centers. A 20-year electricity agreement with Microsoft, alongside deals with Amazon and Alphabet, underpins this strategy. Offsetting tailwinds are elevated financing needs, planned equity issuance, and cost pressures from a severe August storm in Indiana. From what I see, the data center angle is worth monitoring closely over the longer term.
The core contrast between these two stocks is cyclical growth versus regulated stability. HSIC is a healthcare distribution business with a lower beta (about 0.84), cyclical exposure to dental and medical procedure volumes, and a restructuring-driven margin story. Its growth is tied to organic volume, private-label penetration, and disciplined acquisition activity. NI, by contrast, is a capital-intensive utility offering a forward dividend yield near 2.7% and earnings visibility from regulated rate recovery, but it faces financing risk from its expanded capital plan and dilution from planned equity issuance. On momentum, HSIC has clearly outperformed over the past year, while NI's data center pipeline represents a longer-dated catalyst that may take years to fully contribute. Risk profiles differ sharply: HSIC carries execution and demand-cycle risk, whereas NI carries regulatory, weather, and balance-sheet leverage risk. I’m watching this closely as the relative performance gap continues to widen.
Based on observable factors — including trend consistency, relative performance, analyst sentiment, and the timing of catalysts — Tickeron's AI would likely favor HSIC over NI in the current environment. HSIC's stronger year-to-date and one-year returns, improving earnings trajectory, and broad "Buy" consensus point to more favorable near-term positioning and trend quality. NI's long-term data center growth story is compelling but is largely back-end loaded and carries financing and regulatory execution uncertainty. As always, this is a probabilistic assessment of current conditions rather than a guarantee of future outcomes.
In my view, incorporating systematic tools can add useful perspective when comparing names like these. Tickeron’s AI Trading Bots allow users to review a range of algorithmic strategies, each with its own performance history and ticker focus, helping align automated signals with individual risk preferences and time horizons.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HSIC moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend. In 24 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HSIC as a result. In 65 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
The Moving Average Convergence Divergence Histogram (MACD) for HSIC turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 29 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSIC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
HSIC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 55 cases where HSIC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The 10-day moving average for HSIC crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +3.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSIC advanced for three days, in 160 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 136 of 252 cases where HSIC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HSIC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.038) is normal, around the industry mean (14.423). P/E Ratio (24.870) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (1.715) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.750) is also within normal values, averaging (4.260).
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSIC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a distributer of healthcare products and services
Industry MedicalDistributors